

Allium Medical Solutions

Business update

Business progressing on multiple fronts

Allium Medical has made significant progress across business lines. The safety monitoring board has recommended continuing the study of Gardia's embolic protection device; clinical data will be reported by end Q317. A clinical trial of its urological stents in the local population will not be necessary for approval in China; this is in line with our expectations. We expect sales to start in 2018 via a NIS58m eight-year distribution agreement. Following positive preclinical data, Allevetix is on track to start a clinical trial by year-end 2017. We forecast revenue CAGR of 41% in 2016-20e and expect the company to break even in 2020. Our valuation is NIS1.95-2.08/share.

Year end	Revenue (NISm)	PBT* (NISm)	EPS* (NIS)	DPS (NIS)	P/E (x)	Yield (%)
12/15	5.2	(18.5)	(0.65)	0.0	N/A	N/A
12/16	7.4	(22.0)	(0.49)	0.0	N/A	N/A
12/17e	11.2	(15.7)	(0.30)	0.0	N/A	N/A
12/18e	17.5	(7.1)	(0.13)	0.0	N/A	N/A

Note: *PBT/EPS are normalised, excl. amortisation of acquired intangibles and exceptionals.

Continue trial after positive safety assessment

A Data Safety Monitoring Board (DSMB) has recommended continuation of the study of the Wirion embolic prevention device; clinical data will be reported by end Q317. If data are positive, and FDA approves the product, Wirion will become the only protection system cleared for all atherectomy procedures in the US; at that point, we believe chances to strike a partnership will increase. There is strong interest in the market for atherectomy procedures, as demonstrated by the recent acquisition of Spectranetics Corporation by Philips for a total of €1.9bn.

A step closer to the Chinese and veterinary markets

The Chinese Food and Drug Administration (CFDA) has notified the company of the exemption to conduct a clinical trial in the local population. Therefore, Allium is on track for potential approval by this year's end and launch next year, as we expected. This will start the eight-year collaboration with Allium's distribution partner in China, worth NIS58m. Separately, Allium will enter the veterinary market after signing a global exclusive agreement with the American company Infiniti Medical for distribution of its stents for veterinary use, worth at least NIS1m over five years.

Allevetix and TruLeaf: Expanding the opportunities

The company has increased its rights and participation with the National University of Singapore (NUS) in the Allevetix R&D project from 50% to 100%. Allium has established a new company dedicated to this project with participation of senior management from the NUS and the National Hospital of Singapore. A clinical trial is due to start by end 2017. Additionally, the Israel Innovation Authority has approved a NIS2m non-dilutive grant for TruLeaf, Allium's subsidiary, which is developing a mitral valve replacement device. A trial in large animals is due later this year.

Valuation: DCF of NIS1.95-2.08/share unchanged

We maintain our DCF valuation of NIS1.95-2.08/share. We estimate end-2016 cash of NIS23.2m should be sufficient to fund operations into 2019, at which point further funds will be required depending on growth rates and cost control.

Medical devices


23 July 2017

Price* **NIS1.10**
Market cap **NIS58m**

*Priced at 18 July 2017

	US\$/NIS3.58
Net cash (NISm) at end 2016	23.2
Shares in issue	52.9m
Free float	55%
Code	ALMD
Primary exchange	TASE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(0.7)	(2.4)	(34.2)
Rel (local)	(2.5)	(7.3)	(36.3)
52-week high/low	NIS1.7	NIS1.1	

Business description

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in various areas: cardiovascular, metabolic, genitourinary and gastrointestinal. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical. Allium markets its products mainly through distribution agreements.

Next events

H117 financial results	August 2017
Regulatory approval in additional markets for Allium and IBI	H217
TruLeaf study in large animals	H217
Gardia clinical trial data	Q317
Start Allevetix first in man clinical trial	Q417

Analysts

Juan Pedro Serrate	+44 (0)20 3681 2534
Jonas Peculius	+44 (0)20 3077 5728

healthcare@edisongroup.com

[Edison profile page](#)

Business progress

DSMB recommends continuing the Wirion trial

The DSMB overseeing Gardia Medical's Wirion trial has unanimously recommended that the study continues, as no safety concerns have been identified. Gardia Medical, a subsidiary of Allium Medical is conducting a clinical trial of the Wirion embolic protection device to expand the current FDA-approved indication (remove embolic material while performing angioplasty and stenting procedures in carotid arteries) to cover lower extremities. The safety assessment has been conducted in 69 subjects. Clinical data are expected to be available by end Q317. We note that the recent acquisition of Spectranetics Corporation by Philips for a total €1.9bn underscores the interest of large corporations in the space. Spectranetics (FY16 revenues of \$271m; EBIT of -\$44m) has a wide portfolio of products that treat blockage of coronary and peripheral arteries by laser and mechanical means. We believe FDA clearance would increase chances of striking a partnership.

Closer to the Chinese market; new entrant in veterinary market

Allium will submit additional technical and regulatory information to the CFDA in the next few weeks aiming for approval by end 2017. This is in line with our forecast launch in 2018. Furthermore, this will initiate the collaboration with Allium's Chinese partner for distribution of urology products. As we published in our [initiation report](#), the agreement involves the purchase of at least NIS58m worth of stents over a period of eight years. The partner will bear commercialisation and marketing costs. We believe this reinforces Allium's business case, particularly in emerging markets where we forecast sales of c NIS132m over the next five to eight years, out of a total of c NIS185m for its peripheral stents and IBI EndoFast urogynecology products. We expect the group of China, Russia and Mexico to grow from sales of NIS0.2m in 2016 to NIS10.4m at a CAGR of 176% into 2020, and become 46% of total revenue. Furthermore, the company has announced a deal with American veterinary company Infiniti Medical for the global distribution of its stents for multiple clinical indications. The deal is worth at least NIS1m over five years. We look to add this deal to our valuation and forecast on release of half-year results in August 2017.

Allevetix increases participation in joint venture to 100%

Allium is developing Allevetix, a gastroduodenal implant, in a joint venture with the NUS. Allevetix is a minimally invasive alternative to gastric bypass surgery for obese Type 2 diabetic patients. The partners have recently signed a conclusive agreement in which Allium's participation has gone from 50% to 100%, granting Allium all IP and commercialisation rights. Allium has established a new subsidiary in which senior management from NUS and the National Hospital of Singapore (NHS) will receive a 7% equity stake. A clinical trial is planned to start in Q417 and a partner will be sought for commercialisation. We believe this is positive for Allium as it allows it to increase the commercial prospects of Allevetix. Allium has informed the market that Michael Ilan, an existing shareholder which holds c 10% of the company's shares, has invested NIS1m in Allevetix at a pre-money valuation of \$7m with a conversion feature to the company's shares. The market for bariatric surgery devices is expected to grow from \$1.4bn in 2015 to \$2.2bn by 2020, according to [BCC Research 2016](#).

TruLeaf

The Israeli Government has approved a NIS2m non-dilutive grant for TruLeaf for the development of its mitral valve replacement device. For the first year of development the grant was approved with the highest applicable participation ratio of 50%. After meeting the specified milestones, the company will apply for additional grants for this project. TruLeaf's development plan will run for three years and is expected to cost \$5-6m until a successful first-in-human study. Allium will

conduct trials of its mitral valve replacement device in big animals this year. We note that Mike Berman has been appointed as a member of the Board of Directors of TruLeaf. He was a president of Boston Scientific's cardiology division and a member of the company's executive committee. An estimated four million people in the US have significant mitral regurgitation, with an incidence of 250,000 new patients/year.

Exhibit 1: Financial summary

	NIS000	2015	2016	2017e	2018e
Year end 31 December		IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS					
Revenue		5,178	7,353	11,196	17,470
Cost of sales		(4,421)	(5,171)	(7,819)	(10,126)
Gross profit		757	2,182	3,377	7,343
EBITDA		(16,333)	(20,375)	(14,728)	(6,299)
Operating profit (before GW and except.)		(16,759)	(20,757)	(15,349)	(6,858)
Intangible amortisation		(1,705)	(1,579)	(1,436)	(1,293)
Exceptionals		(720)	(297)	0	0
Operating profit		(19,184)	(22,632)	(16,784)	(8,151)
Net interest		(1,748)	(1,284)	(361)	(213)
Exceptionals		0	0	0	0
Other		0	0	0	0
Profit before tax (norm)		(18,507)	(22,041)	(15,709)	(7,070)
Profit before tax (IFRS)		(20,932)	(23,917)	(17,145)	(8,363)
Tax		0	0	0	0
Profit after tax (norm)		(18,507)	(22,041)	(15,709)	(7,070)
Profit after tax (IFRS)		(20,932)	(23,917)	(17,145)	(8,363)
Average number of shares outstanding (m)		28.53	44.97	52.94	52.94
EPS – normalised (NIS)		(0.65)	(0.49)	(0.30)	(0.13)
EPS – IFRS (NIS)		(0.73)	(0.53)	(0.32)	(0.16)
Dividend per share (NIS)		0.00	0.00	0.00	0.00
Gross margin (%)		15%	30%	30%	42%
EBITDA margin (%)		N/A	N/A	N/A	N/A
Operating margin (before GW and except.) (%)		N/A	N/A	N/A	N/A
BALANCE SHEET					
Fixed assets		25,612	23,616	21,660	19,908
Intangible assets		24,059	22,465	21,029	19,736
Tangible assets		1,472	1,025	505	46
Restricted cash		81	126	126	126
Current assets		31,342	28,605	13,163	6,981
Stocks		2,277	2,516	2,527	2,834
Debtors		889	1,253	1,534	1,914
Cash		27,053	23,202	7,469	599
Other		1,123	1,634	1,634	1,634
Current liabilities		(5,620)	(12,660)	(12,507)	(13,037)
Creditors		(1,524)	(1,890)	(1,737)	(2,267)
Accruals		(1,895)	(936)	(936)	(936)
Other short-term liabilities		(2,201)	(4,124)	(4,124)	(4,124)
Long-term liabilities		(6,207)	(1,368)	(1,268)	(1,168)
Long-term borrowings		0	0	0	0
Other long-term liabilities		(6,207)	(1,368)	(1,268)	(1,168)
Net Assets		45,127	38,193	21,048	12,685
CASH FLOW					
Operating cash flow		(15,874)	(17,259)	(15,533)	(6,670)
Net interest		0	0	0	0
Tax		0	0	0	0
Capex		(164)	(220)	(100)	(100)
Acquisitions/disposals		0	0	0	0
Financing		31,992	13,956	0	0
Dividends		0	0	0	0
Other		(1,841)	(328)	(100)	(100)
Net cash flow		14,113	(3,851)	(15,733)	(6,870)
Opening net debt/(cash)		(12,940)	(27,053)	(23,202)	(7,469)
HP finance leases initiated		0	0	0	0
Other		0	0	0	0
Closing net debt/(cash)		(27,053)	(23,202)	(7,469)	(599)

Source: Edison Investment Research, Allium Medical Solutions accounts

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting, is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively "the Scheme", "TASE", "Participant" and/or "Participants"). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively "Edison Israel" and "Edison"), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter "the Agreement"), regarding the Participants and according to the Scheme (hereinafter "the Analysis" or "Analyses"). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter "the ISA") website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of \$35,000 -50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property, the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities' regulatory authority which regulates the issuance of securities by the Company to the content of the Report or the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2 Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.